2019 Proliferative Diabetic Retinopathy (PDR) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 94 pages | ID: 24DDA8B5DB2EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Proliferative Diabetic Retinopathy (PDR) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Proliferative Diabetic Retinopathy (PDR). It presents in-depth analysis of Proliferative Diabetic Retinopathy (PDR) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Proliferative Diabetic Retinopathy (PDR).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Proliferative Diabetic Retinopathy (PDR) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Proliferative Diabetic Retinopathy (PDR)

The research work is prepared through extensive and continuous research on Proliferative Diabetic Retinopathy (PDR) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Proliferative Diabetic Retinopathy (PDR) patients are identified
• The report includes panorama of Proliferative Diabetic Retinopathy (PDR) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Proliferative Diabetic Retinopathy (PDR) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Proliferative Diabetic Retinopathy (PDR) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Region
  2.2.2 Average Enrollment of Proliferative Diabetic Retinopathy (PDR) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Proliferative Diabetic Retinopathy (PDR) Treatment, 2019

3. REGION WISE PROLIFERATIVE DIABETIC RETINOPATHY (PDR) CLINICAL TRIALS

3.1 Asia Pacific Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Country
3.2 Europe Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Country
3.3 North America Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Country
3.4 Middle East and Africa Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Country
3.5 South and Central America Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Country

4. PROLIFERATIVE DIABETIC RETINOPATHY (PDR) CLINICAL TRIAL TRENDS

4.1 Start Year wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials
4.2 Phase wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials
4.3 Trial Status wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials
4.4 Trial Type wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials

5. PROLIFERATIVE DIABETIC RETINOPATHY (PDR) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Proliferative Diabetic Retinopathy (PDR) Trials by Year
5.2 Average Enrollment in Proliferative Diabetic Retinopathy (PDR) Trials by Phase
5.3 Average Enrollment in Proliferative Diabetic Retinopathy (PDR) Trials by Status
5.4 Average Enrollment in Proliferative Diabetic Retinopathy (PDR) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN PROLIFERATIVE DIABETIC RETINOPATHY (PDR) CLINICAL TRIALS

6.1 Proliferative Diabetic Retinopathy (PDR) Trials by Sponsor Type
6.2 Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Proliferative Diabetic Retinopathy (PDR) Trials- Phase
7.2 Proliferative Diabetic Retinopathy (PDR) Trials- Phase
7.3 Proliferative Diabetic Retinopathy (PDR) Trials- Phase
7.4 Proliferative Diabetic Retinopathy (PDR) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Figure 7: North America – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Figure 9: Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Phase
Figure 10: Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Trial Status
Figure 11: Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Type
Figure 12: Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Sponsor Type
Figure 13: Proliferative Diabetic Retinopathy (PDR) Clinical Trials by Leading Sponsors
Figure 14: Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Phase
Figure 15: Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Trial Status
Figure 16: Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Type
Figure 17: Proliferative Diabetic Retinopathy (PDR)- Average Enrolment by Type of Sponsors
Figure 18: Proliferative Diabetic Retinopathy (PDR)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Proliferative Diabetic Retinopathy (PDR) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Table 5: Europe – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Table 7: North America – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Proliferative Diabetic Retinopathy (PDR) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Phase
Table 15: Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Trial Status
Table 16: Proliferative Diabetic Retinopathy (PDR) Average Enrollment by Type
Table 17: Proliferative Diabetic Retinopathy (PDR)- Average Enrolment by Type of Sponsors
Table 18: Proliferative Diabetic Retinopathy (PDR)- Enrolment by Leading Sponsors